Active Surveillance: Recent Findings and Case Studies - Laurence Klotz

January 24, 2019

In this interview, Laurence Klotz discusses patients who have yet to be treated but have been diagnosed or in the process of being diagnosed with prostate cancer. Dr. Klotz reviews different case studies including treating a patient with mild elevation of PSA, age-adjusted norms, the use of a risk nomogram in determining significant cancer and deciding on a path of active surveillance. They also discuss the use of MRI for elevated levels of PSA, the importance of age in selecting active surveillance and lastly the importance of risk factors such as family history, race, a patient’s lifestyle, PSA density and the extent of core volume, and underlying co-morbidities.

Biographies:

Laurence Klotz is a Professor in the Department of Surgery at the University of Toronto. He serves as President of the Canadian Urology Research Consortium, Chairman of the World Uro-Oncology Federation and the Editor Emeritus of the Canadian Urological Association Journal. He served as Chief of Urology at Sunnybrook Health Sciences Centre and is a renowned clinician in the area of Active Surveillance. Dr. Klotz was awarded the Order of Canada, the highest civilian award in Canada for his prolific, distinguished work.

John Fortin, Retired Healthcare Actuary, Fellow in the Society of Actuaries, and Patient-Advocate and Henry Oat, Clinical Trial - Patient Coordinator at Desert Medical Imaging, Prostate Cancer Support Group Leader and Patient-Advocate. Both John and Henry are prostate cancer survivors.